<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116476</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-A02</org_study_id>
    <nct_id>NCT04116476</nct_id>
  </id_info>
  <brief_title>Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function</brief_title>
  <official_title>An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and&#xD;
      Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic&#xD;
      Function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">February 16, 2021</completion_date>
  <primary_completion_date type="Actual">February 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to the time of last quantifiable concentration (AUC0-last) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to infinity (AUC0-âˆž) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma terminal elimination half-life (t1/2) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fraction of unbound drug in plasma or serum (fu) of MT-7117</measure>
    <time_frame>0-96 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>0-96 Hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Mild and Moderate Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Healthy Matches</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117</intervention_name>
    <description>Single Dose of MT-7117</description>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal Healthy Matches</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects 18 to 75 years of age inclusive&#xD;
&#xD;
          -  BMI 18 -35 kg/m2&#xD;
&#xD;
          -  If female, you are nonpregnant, non-lactating and willing to utilize approved methods&#xD;
             of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have mild or moderate hepatic impairment according to Child-Pugh&#xD;
             classification system at Screening (except normal healthy matches)&#xD;
&#xD;
          -  Subjects who have a known clinically significant (CS) hypersensitivity to MT-7117 or&#xD;
             related compounds, including melatonin.&#xD;
&#xD;
          -  Subjects who have previously participated in a study involving MT-7117 or taken any&#xD;
             other investigational drug within 30 days or 5 half-lives prior to the first dose of&#xD;
             IMP, whichever is longer.&#xD;
&#xD;
          -  Subjects who have a CS or unstable neurological, renal, cardiovascular,&#xD;
             gastrointestinal, pulmonary, or hematologic disease for 14 days prior to enrollment.&#xD;
&#xD;
          -  Subjects who have used any prescription or over-the-counter (OTC) medication within 14&#xD;
             days prior to first dose of IMP, except for occasional use of acetaminophen (&lt; 1 g/day&#xD;
             for normal hepatic subjects, and &lt; 2 g/day for hepatically impaired subjects) or any&#xD;
             other medication approved by the sponsor (a case-by-case basis). For hepatic impaired&#xD;
             subjects, prescribed medication or OTC may be permitted by the Investigator and&#xD;
             sponsor on a case-by-case basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Development,</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Clinical Pharmacology Unit</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

